Angelini Ventures logo

Angelini Ventures

Europe, Lazio, Italy, Rome

Description

Angelini Ventures is an investment firm.

Investor Profile

Angelini Ventures has backed more than 18 startups, with 9 new investments in the last 12 months alone. The firm has led 6 rounds, about 33% of its total and boasts 0 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series A, Series B, Series C rounds (top funding stages).
  • Majority of deals are located in United States, Italy, Switzerland.
  • Strong thematic focus on Health Care, Therapeutics, Biotechnology.
  • Led 4 rounds in the past year.

Stage Focus

  • Series A (39%)
  • Series B (17%)
  • Series C (17%)
  • Seed (17%)
  • Pre Seed (6%)
  • Series Unknown (6%)

Country Focus

  • United States (44%)
  • Italy (22%)
  • Switzerland (6%)
  • Belgium (6%)
  • Denmark (6%)
  • Germany (6%)
  • Singapore (6%)
  • France (6%)

Industry Focus

  • Health Care
  • Therapeutics
  • Biotechnology
  • Medical
  • Pharmaceutical
  • Medical Device
  • Neuroscience
  • Health Diagnostics
  • Mobile Devices
  • Wearables
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Angelini Ventures frequently co-invest with?

Bristol-Myers Squibb
North America, New York, United States, New York
Co-Investments: 1
Asahi Kasei
Asia, Tokyo, Japan, Tokyo
Co-Investments: 2
JDRF T1D Fund
North America, Massachusetts, United States, Boston
Co-Investments: 1
Lumira Ventures
North America, Ontario, Canada, Toronto
Co-Investments: 1
TI
Europe, Bayern, Germany, Munich
Co-Investments: 2
Kurma Partners
Europe, Ile-de-France, France, Paris
Co-Investments: 2
AW
North America, Florida, United States, Miami
Co-Investments: 1
Bayern Kapital
Europe, Bayern, Germany, Landshut
Co-Investments: 2
Roche Venture Fund
Europe, Basel-Stadt, Switzerland, Basel
Co-Investments: 1

Which angels does Angelini Ventures often collaborate with?

AC
Europe, Lombardia, Italy, Milan
Shared Deals: 1

What are some of recent deals done by Angelini Ventures?

Nuclidium

Basel, Basel-Stadt, Switzerland

Nuclidium is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics.

Health CareHealth DiagnosticsMedicalTherapeutics
Series BJul 10, 2025
Amount Raised: $99,518,156
Elkedonia

Strasbourg, Alsace, France

Elkedonia is a biotech company dedicated to transforming antidepressant therapy.

BiotechnologyHealth CareMedical
SeedJun 11, 2025
Amount Raised: $12,842,202
Therini Bio

San Francisco, California, United States

Therini Bio specializes in fibrin-targeting therapies to treat inflammatory neurological and retinal diseases.

BiotechnologyHealth CareMedicalTherapeutics
Series AMay 14, 2025
Amount Raised: $39,000,000
Nuevocor

Singapore, Central Region, Singapore

Nuevocor operates as a preclinical-stage biotech company.

BiopharmaBiotechnologyMedicalPharmaceutical
Series BMay 6, 2025
Amount Raised: $45,000,000
Biovitae

Salerno, Campania, Italy

Biovitae focuses on infection control and prevention, as well as combating antimicrobial resistance.

Health CareHealth DiagnosticsTherapeutics
Series AApr 22, 2025
Amount Raised: $5,675,478
Vantis Vascular

San Jose, California, United States

Vantis Vascular develops technology for vascular interventions targeting complex arteries.

AppsHealth CareInformation TechnologyMedicalMedical Device
Series UnknownMar 12, 2025
Amount Raised: $10,885,681
Vantis

Munich, Bayern, Germany

Vantis is a digital solution for chronic cardiovascular diseases that requires personalized ongoing treatment for decades.

Health Care
Series AMar 12, 2025
Amount Raised: $10,911,539
Nobi

Antwerpen, Antwerpen, Belgium

Nobi is an AI-powered smart lamp.

Artificial Intelligence (AI)
Series BJan 28, 2025
Amount Raised: $36,510,589
Neumirna Therapeutics

Copenhagen, Hovedstaden, Denmark

Neumirna Therapeutics is a Danish pharmaceutical start-up based in Copenhagen.

Pharmaceutical
Series AJan 8, 2025
Amount Raised: $20,708,264
Aptadir Therapeutics

Milan, Lombardia, Italy

Aptadir Therapeutics is developing a treatment for Myelodysplastic Neoplasms based on the capability of specific RNA therapeutics.

BiotechnologyHealth CareMedical
Pre SeedSep 24, 2024
Amount Raised: $1,600,000